Den andel af patienter, der fik behandling med Enbrel, og som udviklede anticaridolipin- antistoffer, steg i samme omfang som for patienter, der fik placebo.
The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.